Team Science and Accelerated Vaccine Introduction in Cuba: A View from the Pneumococcal Project.

Team Science and Accelerated Vaccine Introduction in Cuba: A View from the Pneumococcal Project. MEDICC Rev. 2019 Jan;21(1):37-38 Authors: Linares-Pérez N Abstract The process of research and evaluation of new products and technologies requires a combination of transdisciplinary theoretical and methodological approaches for managing and achieving objectives. The research, development and evaluation strategy of the new Cuban pneumococcal vaccine combines the approaches of team science and accelerated vaccine introduction. These frameworks are proposed for discussions regarding biotech product evaluation, using their application to the Pneumococcus Project as an example. Emphasis is on the use of team science to eliminate obstacles to obtaining a product of great scientific and technological complexity while establishing robust scientific evidence to support its use and marketing. All of this is in support of opportune and efficient decisions for accelerated introduction of new vaccines in Cuba. PMID: 31242151 [PubMed - in process]
Source: MEDICC Review - Category: International Medicine & Public Health Tags: MEDICC Rev Source Type: research

Related Links:

Conclusions: The PHiD-CV vaccination program in Brazil has resulted in important reductions of pneumococcal disease and substantial cost savings. Instead of switching PCVs, expanding vaccine coverage or investing in other health care interventions would be a more efficient use of resources to improve the health of the population in Brazil.
Source: The Pediatric Infectious Disease Journal - Category: Infectious Diseases Tags: Vaccine Reports Source Type: research
Acute otitis media is one of the most common childhood infections worldwide. Currently licensed vaccines against the common otopathogen Streptococcus pneumoniae target the bacterial capsular polysaccharide and confer no protection against nonencapsulated strains or capsular types outside vaccine coverage. Mucosal infections such as acute otitis media remain prevalent, even those caused by vaccine-covered serotypes. Here, we report that a protein-based vaccine, a fusion construct of epitopes of CbpA to pneumolysin toxoid, confers effective protection against pneumococcal acute otitis media for non-PCV-13 serotypes and enhan...
Source: Infection and Immunity - Category: Infectious Diseases Authors: Tags: Microbial Immunity and Vaccines Source Type: research
Authors: Autran B Abstract The aging population raises a number of public health issues including a need to address the severity and frequency of infections observed in older people. Vaccines play an important role in prevention. However, immunosenescence alters the intensity and quality of vaccine responses, thus limiting the impact of recommendations directed after 65 years for vaccination against flu, pneumococci, pertussis, tetanus and zoster. Immunosenescence, aggravated by co-morbidities, varies with age, becoming apparent after 60-65 years and more profound after 85 years. All stages of vaccine responses are...
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
Abstract Acute otitis media (AOM) is the most common diagnosis in childhood acute sick visits. By three years of age, 50% to 85% of children will have at least one episode of AOM. Symptoms may include ear pain (rubbing, tugging, or holding the ear may be a sign of pain), fever, irritability, otorrhea, anorexia, and sometimes vomiting or lethargy. AOM is diagnosed in symptomatic children with moderate to severe bulging of the tympanic membrane or new-onset otorrhea not caused by acute otitis externa, and in children with mild bulging and either recent-onset ear pain (less than 48 hours) or intense erythema of the t...
Source: American Family Physician - Category: Primary Care Authors: Tags: Am Fam Physician Source Type: research
Conditions:   Pneumonia;   Respiratory Tract Diseases;   Respiratory Tract Infections Interventions:   Biological: Protein based pneumococcal vaccine(Low dose);   Biological: Protein based pneumococcal vaccine placebo(Low dose);   Biological: Protein based pneumococcal vaccine(Middle dose);   Biological: Protein based pneumococcal vaccine placebo(Middle dose);   Biological: Protein based pneu mococcal vaccine(High dose);   Biological: Protein based pneumococcal vaccine placebo(High dose) Sponsors:   CanSino Biologics Inc.;   Henan Cen...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Pneumonia;   Respiratory Tract Diseases;   Respiratory Tract Infections Interventions:   Biological: Protein based pneumococcal vaccine(Low dose);   Biological: Protein based pneumococcal vaccine placebo(Low dose);   Biological: Protein based pneumococcal vaccine(Middle dose);   Biological: Protein based pneumococcal vaccine placebo(Middle dose);   Biological: Protein based pneu mococcal vaccine(High dose);   Biological: Protein based pneumococcal vaccine placebo(High dose) Sponsors:   CanSino Biologics Inc.;   Henan Cen...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Pneumonia;   Respiratory Tract Diseases;   Respiratory Tract Infections Interventions:   Biological: Protein based pneumococcal vaccine(Low dose);   Biological: Protein based pneumococcal vaccine placebo(Low dose);   Biological: Protein based pneumococcal vaccine(Middle dose);   Biological: Protein based pneumococcal vaccine placebo(Middle dose);   Biological: Protein based pneu mococcal vaccine(High dose);   Biological: Protein based pneumococcal vaccine placebo(High dose) Sponsors:   CanSino Biologics Inc.;   Henan Cen...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Pneumonia;   Respiratory Tract Diseases;   Respiratory Tract Infections Interventions:   Biological: Protein based pneumococcal vaccine(Low dose);   Biological: Protein based pneumococcal vaccine placebo(Low dose);   Biological: Protein based pneumococcal vaccine(Middle dose);   Biological: Protein based pneumococcal vaccine placebo(Middle dose);   Biological: Protein based pneu mococcal vaccine(High dose);   Biological: Protein based pneumococcal vaccine placebo(High dose) Sponsors:   CanSino Biologics Inc.;   Henan Cen...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Pneumonia;   Respiratory Tract Diseases;   Respiratory Tract Infections Interventions:   Biological: Protein based pneumococcal vaccine(Low dose);   Biological: Protein based pneumococcal vaccine placebo(Low dose);   Biological: Protein based pneumococcal vaccine(Middle dose);   Biological: Protein based pneumococcal vaccine placebo(Middle dose);   Biological: Protein based pneu mococcal vaccine(High dose);   Biological: Protein based pneumococcal vaccine placebo(High dose) Sponsors:   CanSino Biologics Inc.;   Henan Cen...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Pneumonia;   Respiratory Tract Diseases;   Respiratory Tract Infections Interventions:   Biological: Protein based pneumococcal vaccine(Low dose);   Biological: Protein based pneumococcal vaccine placebo(Low dose);   Biological: Protein based pneumococcal vaccine(Middle dose);   Biological: Protein based pneumococcal vaccine placebo(Middle dose);   Biological: Protein based pneu mococcal vaccine(High dose);   Biological: Protein based pneumococcal vaccine placebo(High dose) Sponsors:   CanSino Biologics Inc.;   Henan Cen...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Cuba Health | International Medicine & Public Health | Marketing | Meningitis Vaccine | Pneomococcal Vaccine | Science | Vaccines